Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars. Authors’ reply

J. Goncalves; F. Magro; S. Danese; P. L. Lakatos; S. Ben-Horin

doi:10.1111/apt.14860

Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars. Authors’ reply

J. Goncalves, F. Magro, S. Danese, P. L. Lakatos, S. Ben-Horin

Internal Medicine

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	575-576
Number of pages	2
Journal	Alimentary Pharmacology and Therapeutics
Volume	48
Issue number	5
DOIs	https://doi.org/10.1111/apt.14860
State	Published - Sep 2018

Access to Document

10.1111/apt.14860

Cite this

@article{550c2882418942cfbbcad8454443f743,

title = "Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars. Authors{\textquoteright} reply",

author = "J. Goncalves and F. Magro and S. Danese and Lakatos, {P. L.} and S. Ben-Horin",

year = "2018",

month = sep,

doi = "10.1111/apt.14860",

language = "אנגלית",

volume = "48",

pages = "575--576",

journal = "Alimentary Pharmacology and Therapeutics",

issn = "0269-2813",

publisher = "John Wiley and Sons Inc.",

number = "5",

}

Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars. Authors’ reply. / Goncalves, J.; Magro, F.; Danese, S. et al.
In: Alimentary Pharmacology and Therapeutics, Vol. 48, No. 5, 09.2018, p. 575-576.

Research output: Contribution to journal › Editorial

TY - JOUR

T1 - Editorial

T2 - antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars. Authors’ reply

AU - Goncalves, J.

AU - Magro, F.

AU - Danese, S.

AU - Lakatos, P. L.

AU - Ben-Horin, S.

PY - 2018/9

Y1 - 2018/9

UR - http://www.scopus.com/inward/record.url?scp=85051276943&partnerID=8YFLogxK

U2 - 10.1111/apt.14860

DO - 10.1111/apt.14860

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.editorial???

C2 - 30156326

AN - SCOPUS:85051276943

SN - 0269-2813

VL - 48

SP - 575

EP - 576

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

IS - 5

ER -

Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars. Authors’ reply

Access to Document

Other files and links

Cite this